Coherus BioSciences, Inc. announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the iPROC platform study. Under the terms of a clinical supply agreement with the Cancer Research Institute (Cri), Coherus will supply LOQTORZI for combination treatment with ENB-003 to be investigated in the iPROC platform trial. The IPROC clinical trial uses an adaptive platform study that utilizes a single master protocol to evaluate multiple immunotherapy combinations.

This allows multiple treatments to be evaluated in different groups of patients, or cohorts, from the same patient population. Such a study design offers flexibility in that different treatments can be evaluated in different cohorts, treatment regimens can be modified between cohorts, and treatment selection criteria can be customized for a specific cohort. The trial, titled Immunotherapy Platform Study in Platinum -Resistant High-Grade Seralous Ovarian Cancer (IP ROC) (NCT04918186), has two ongoing cohorts.

Coherus' immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innovate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in two ongoing clinical studies: a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, cytolytic anti-CCR8 antibody currently in a Phase 1 study in patients with advanced solid tumors.

Coherus markets LOQTORZI (tor principalimab-tpzi), a novel next-generation PD-1 inhibitor, UDENYCA®? (pegfilgrastim-cbqv), a biosimilar of Neulasta®?, and YUSIMRY®? (adalimumab-aqh), a biosimilar of Humira®?.